IndustryCompany release

Helus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation rises

Helus Pharma Inc. (HELP) · Fri 13 Nov 2026

The company formerly known as Cybin ended September 2026 with $171.1M in cash, up from March, after about $86M in net equity proceeds.

Helus Pharma Inc., formerly Cybin, has published unaudited interim financial statements for the six months ended 30 September 2026. The company's board approved them on 12 November 2026.

Net loss for the period reached $150.9M, against $58.3M a year earlier. The company attributes the increase to higher research spending and to greater non-cash share-based compensation, largely linked to the vesting of restricted share units.

Cash stood at $171.1M at 30 September, compared with $157.3M at 31 March. The rise followed roughly $86M of net proceeds from equity financing, which included an at-the-market offering.

The summary available does not break down research spending by programme or give guidance on future funding needs, so the figures say little about clinical timelines.

What it means for your team

  • Much of the widened loss is non-cash share-based compensation, so it does not by itself indicate a faster burn on development work.
  • Higher research spending is cited as a contributor, which teams tracking the company's development activity may wish to follow in the full filing.
  • Equity raising, including an at-the-market offering, funded the cash increase; partners and counterparties may note the company's continued reliance on capital markets.

Company's press release (SEC filing): Helus Pharma Inc. ↗

Article written by VigiEye from the official source (Helus Pharma Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →